Patterns of Treatment Choices and Outcomes for Biguanides and SGLT2 Inhibitors

Overview

This retrospective analysis investigates treatment selection and outcomes for biguanides and SGLT2 inhibitors in Japanese patients with type 2 diabetes.

Background

Type 2 diabetes mellitus (T2DM) is a significant global health issue, with Japan experiencing rising incidence rates. Effective management is crucial to prevent complications and reduce healthcare costs.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Cardiovascular risk is a primary driver for treatment selection.
• Biguanides showed a reduction in HbA1c at 24 weeks compared to SGLT2 inhibitors.
• SGLT2 inhibitors demonstrated higher treatment persistence over 48 weeks in the first-line cohort.
• Prescription rates for DPP-4 inhibitors are decreasing, while biguanides and SGLT2 inhibitors are increasing.
• Current guidelines lack specific numerical criteria for medication selection.

Clinical Implications

Clinicians should consider cardiovascular risk when selecting treatments for T2DM, as it may influence patient outcomes. The findings highlight the need for clearer guidelines to aid in medication selection, particularly for non-specialists.

Conclusion

This study presents findings on treatment patterns and outcomes for biguanides and SGLT2 inhibitors in Japan.

Related Resources & Content

1. Frontiers in Endocrinology, 2026 -- Clinical efficacy, safety, and predictors of treatment response to SGLT2 versus DPP-4 inhibitors in type 2 diabetes
2. conexiant -- SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis
3. Drugs - Real World Outcomes -- Association of Sodium-Glucose Cotransporter-2 Inhibitors with Decreased Heart Failure Hospitalization Risk in Patients with Preserved Ejection Fraction and Type 2 Diabetes Mellitus
4. Frontiers in Endocrinology, 2026 -- SodiuM glucose cotrANsporter-2 (SGLT-2) inhibitors in the treatment of type II DiAbetes in Tuscany: utiLizatiOn patteRns, and relatEd clinical use evaluation; the MANDALORE study protocol
5. 日本糖尿病学会誌第66巻第10号 -- 日本糖尿病学会の薬物療法に関するコンセンサスアルゴリズム
6. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 | Diabetes Care | American Diabetes Association
7. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis
8. 日本糖尿病学会誌第66巻第10号
9. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 | Diabetes Care | American Diabetes Association
10. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis